Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients' treatment options and lives.
BASKING RIDGE, N.J. , July 15, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has filed a "universal shelf" registration statement on Form S-3 (the “Registration Statement”) with the Securities and Exchange
BASKING RIDGE, N.J. , July 10, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a global commercial-stage bioelectronic medicine company, today announced data presentations focused on non-invasive vagus nerve stimulation (nVNS) to be presented at the American Headache Society’s 61 st
The National Institute for Health and Care Excellence (NICE) draft guidance recommends the use of gammaCore for cluster headache in the National Health Service (NHS) LONDON and BASKING RIDGE, N.J. , July 09, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a global commercial-stage
LONDON , and BASKING RIDGE, N.J. , June 24, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore TM , the company’s non-invasive vagus nerve stimulator (nVNS), will appear on the NHS Supply
BASKING RIDGE, N.J. , June 10, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Frank R. Amato will be stepping down as Chief Executive Officer. Mr. Amato joined electroCore in 2012 and was named Chief Executive
Management to host conference call and webcast at 8:30am ET on Thursday, May 30 BASKING RIDGE, N.J. , May 29, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that management and the Board of Directors are making
Continues to deliver sequential growth in covered lives, prescribing physicians and FSS facilities Company to host conference call and webcast today, May 14 , at 4:30pm ET BASKING RIDGE, N.J. , May 14, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
Conference Call to be Held at 4:30pm Eastern Time BASKING RIDGE, N.J. , May 08, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report first quarter ended March 31, 2019 financial results after the close of the
gammaCore™ chosen by NHS England to be funded by the Innovation and Technology Payment Program (ITP) for the period of April 2019 to April 2020 to support adoption in the U.K. LONDON and BASKING RIDGE, N.J. , May 06, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), a
BASKING RIDGE, N.J. , May 03, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that two oral presentations featuring non-invasive vagus nerve stimulation (nVNS) will be presented at the 71 st Annual Meeting of the American
